EcoR1 Capital — Full Portfolio

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

AnhCo Nguyen(President and Chief Executive Officer)

Co-investorsDADag VenturesHEHEALTHCARE ROYALTY PARTNERSKLKleiner PerkinsDODomain AssociatesFIFidelity Investments

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

PSPaul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardANAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCACardinal PartnersSOSofinnova VenturesDODomain AssociatesDODomain PartnersPOPolaris PartnersSASamsara BioCapital+1 more

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

MHMichael Heffernan(Executive Officer, Director)inPBPaul Brannelly(Executive Officer)inVKVikram Karnani(President and Chief Executive Officer, and Director)in

BoardEran Nadav(Director)John Freund(Director)PHPatrick Heron(Director)in

Co-investorsAPAPERTURE Venture PartnersFRFrazier Life SciencesLOLongitude CapitalBOBoston Millennia PartnersRARA Capital

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)MGMark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)

Co-investorsPAPappas CapitalABAberdare VenturesINInvusPOPolaris Partners

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

MTMarc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAOAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSESteve E. Krognes(Director)in

Co-investorsARARCH Venture PartnersF-F-Prime CapitalFOForesite CapitalARARCH VentureFLFlagship PioneeringFLFlagship Ventures+1 more

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)inGCGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDLDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKBKatrine Bosley(Executive Officer, Director)inVMVic Myer(Executive Officer)in

Co-investorsSOSofinnova VenturesDEDeerfield Management CompanyFLFlagship VenturesPOPolaris Partners

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

RERiley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGOGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRARA CapitalAGAgent CapitalAMAME Cloud VenturesANAndreessen HorowitzARArtis VenturesASAsset Management Company+9 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)SASamsara BioCapitalOMOmega Funds

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAGage1ATAtlas VentureAVAvoro Capital AdvisorsFOForesite CapitalFIFidelity InvestmentsOROrbiMed

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TWTROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTETroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsFOForesite CapitalNENextech InvestOUOUP (Osage University Partners)ARARCH Venture

Neurogene develops gene therapy treatments for rare neurological diseases.

BiotechDeep TechDigital HealthLongevityMedical Devices

RMRachel McMinn(Founder and Chief Executive Officer)inRMRachel McMinn, Ph.D.(Founder and Chief Executive Officer)

Co-investorsCACasdin CapitalREREDMILERTRTW Investments L.P.

Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.

BiotechHealthtechNew York, US

DHDavid Hung(Founder)inDHDavid Hung, M.D.(Executive Officer, Director)inDavid Hanley(Chief Technical Operations Officer)inGHGary Hattersley(Chief Scientific Officer)inSMStacy Markel(Chief People Officer)inPSPhilippe Sauvage(Chief Financial Officer)in

Co-investorsAIAisling CapitalDEDecheng CapitalVEVertex Ventures ChinaOMOmega Funds

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsNENew Enterprise Associates (NEA)NENextech InvestTATaiho Ventures, LLCTHThe Column GroupOROrbiMed

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSKSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCOCommonweal VenturesFOForesite CapitalNENextech InvestSOSoftBank Vision FundCUCurie.BioGEGeneral Catalyst+1 more

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

NMNagesh Mahanthappa(Executive Officer, Director)inTSTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAVAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVSVikas Sinha(Chief Financial Officer)in

Co-investorsAIAisling CapitalARARCH Venture PartnersARARCH VenturePOPolaris Partners

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Co-investorsSASamsara BioCapitalARARCH VentureARARCH Venture PartnersPOPolaris Partners

Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.

BiotechHealthtechAustin, US

JHJosiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)

BoardWalter Loewenbaum(Director)

Co-investorsHAHatteras Venture PartnersOROrbiMedREREDMILET.T. Rowe Price

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)AHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inANAmeet Nathwani, M.D.(Executive Officer, Director)in

Co-investorsARARCH Venture PartnersSASamsara BioCapital6 6 Dimensions CapitalGEGeneral CatalystINInnovation EndeavorsLELeaps by Bayer+5 more

Epikast provides AI-powered tools for medical science liaisons and field teams to analyze clinical interactions with physicians and patients, and to access synthesized scientific information in their disease areas.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBrooklyn, US

Evangelos Vergetis(Executive Officer, Director)

BoardBrad Prosek(Director)Stelios Papadopoulos(Director)Daphne Karydas(Director)Alexandros Tzoukas(Director)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsVEVedanta Capital

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsAJAju IB Invesment CorporationEVEvolution VC PartnersMPMPM BioImpactOROrbiMedOUOUP (Osage University Partners)PFPfizer Venture Investments+6 more

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Board seatONOleg Nodelman· per SEC Form D

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsFRFrazier Life SciencesNENextech InvestVIVida VenturesABAbingworth+3 more

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsATAtlas VentureDRDroia VenturesGVGV (Google Ventures)THThe Column GroupJJJJDCJOJohnson & Johnson Innovation – JJDC+1 more

Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.

BiotechDeep Tech

DBDavid Breckenridge(Founder)in

Co-investorsCACanaan Partners

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)ATAaron Tward, M.D., Ph.D.(Scientific Co-Founder)BRBotond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)RDRami Daoud(Executive Officer)inRMRick Modi(Chief Executive Officer, Board Member)

Co-investorsATAtlas VentureEIEight Roads VenturesF-F-Prime CapitalGVGV (Google Ventures)NENew Enterprise Associates (NEA)TCTCG Crossover+1 more

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)SBSteven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBABain Capital Life SciencesFOForesite CapitalBABain CapitalRORock Springs CapitalT.T. Rowe Price

Ajax Systems produces wired and wireless intrusion protection devices for professional security installations, offered through two product lines: Baseline for general projects and Ajax Superior for advanced, high-security applications that require partner accreditation and training.

AI & Machine LearningCybersecurityEnterprise SoftwareHardwareIoT

Co-investorsENEndeavor CatalystHOHorizon Capital

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsINInning One VenturesVIVivo Capital

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEMEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesNENew Enterprise Associates (NEA)RARA CapitalSOSofinnova VenturesCOCowen Healthcare InvestmentsFIFidelity Investments+1 more

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechDigital HealthMedical DevicesBerkeley Heights, US

NFNapoleone Ferrara(Director & Co-Founder)SASrinivas Akkaraju(Director & Co-founder)MDMike Dybbs(Director & Co-founder)

A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.

BiotechDigital HealthHealthtechMedical DevicesMental HealthIndianapolis, US

JGJaswant Gidda(Executive Officer, Director)inJames Schulz(Executive Officer)Yvonne Lai(Executive Officer)

BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesFOForesite CapitalSLSLVCSOSofinnova Ventures+2 more

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)FAFred Aslan(Executive Officer, Director)inJLJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)PFPeter Flynn(Executive Officer)in

Co-investors5A5AM VenturesRARA CapitalVEvenBio PartnersVEvenBio Global Strategic

BiotechRedwood City, US

William Robinson(Director)LSLawrence Steinman(Director)TSTito Serafini(Executive Officer, Director)

BoardBrian Atwood(Director)Franklin Berger(Director)

Co-investorsAIAisling CapitalEVEvolution VC PartnersMIMission Bay CapitalMIMission Biocapital

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsFRFrazier Life SciencesILIllumina VenturesNENextech InvestSASanofi VenturesVIVida VenturesGOGoldman Sachs+1 more

AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases.

BiotechDigital HealthHealthtechMedical Devices

George Montgomery(Executive Chairman)

Co-investorsEVEvolution VC PartnersHEHelios CapitalPLPlum Alley InvestmentsSASand Hill AngelsSOSocii CapitalTRTribe Capital Firstlook

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Co-investorsAIAisling CapitalAMAmzak HealthFRFrazier Life SciencesHEHEALTHCARE ROYALTY PARTNERSLOLongwood FundSESequoia Capital

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.

Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US

FGFabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOKOmar Kurdi(Co-Founder and President)in

BoardJBJustin Butler(Director)inVTVictor Tong(Director)in

Co-investorsDEDecheng Capital8V8VCINIntuitive VenturesKOKoch Disruptive TechnologiesBABaillie GiffordBLBlackRock+4 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesFOForesite CapitalMEMedicxiOBOberland CapitalSCScion Life SciencesVIVida Ventures+1 more

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

DWDoug Williams(Executive Officer, Director)in

BoardNANoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsARARCH Venture PartnersFLFlagship Pioneering

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

CNChiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsPAPacific Channel3E3E Bioventures CapitalARARCH Venture PartnersGEGeneral CatalystLELeaps by BayerMAMaverick Ventures+2 more

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Co-investorsATAtlas VentureFRFrazier Life SciencesSASanofi Ventures

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

DHDavid Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in

Co-investorsMPMPM BioImpactSASamsara BioCapitalSOSoftBank Vision Fund

Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.

BiotechDigital HealthHealthtechMedical Devices

Dr. Rod MacKinnon(Founder)

Co-investorsBEBessemer Venture PartnersLILightstone VenturesLOLongwood Fund

BiotechSouth San Francisco, US

JFJohn F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)

BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)

Co-investorsBABay City CapitalCHChiesi VenturesPAPappas CapitalSOSolasta VenturesQIQiming Venture Partners

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsGVGV (Google Ventures)NENextech InvestVIVida VenturesBLBlackRockCOCommodore CapitalINInvus+1 more

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)inYLYi Liu, Ph.D.(CEO)Lynn Yang(Director)

BoardCGCarl Gordon(Director)in

Co-investorsOROrbiMedRORoche Venture Fund

A Korean-language service that brokers in-game currency ("money") and poker chips for the Pmang and Hangame poker platforms, letting players buy game money or cash out their holdings.

GamingMarketplaces

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsAGage1LALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)VIVivo CapitalARARCH Venture Partners+2 more

HealthtechWest Lafayette, US

Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)RMRonald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)

Co-investorsARArsenal Bridge VentureJAJanus Henderson InvestorsREREDMILE

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCOCota CapitalLALatterell Venture PartnersSOSofinnova VenturesADAdams Street Partners

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDMDavid M. Tanen(Director, Promoter)HKHelen Kim(Director)

Co-investorsJEJeito CapitalVIVida VenturesTPTPG

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)H(Hong (Kelsey) Chen(Chief Financial Officer)

BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)

Co-investorsLALAVLILilly Asia VenturesRARA CapitalSASamsara BioCapitalTHThe Innovation SpaceLOLogos

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBABain Capital Life SciencesFOForesite CapitalSOSofinnova VenturesTHThe Column Group

Omniox is an IND-stage biotherapeutics company developing its H-NOX platform into OMX oxygen delivery biologics that carry oxygen to hypoxic tissues where low oxygen levels drive disease.

BiotechMedical DevicesSan Francisco, US

JWJonathan Winger(Executive Officer, Director)inStephen Cary(Executive Officer, Director)

BoardJeffrey S. Samberg(Director)Laurence Marton(Director)Mitchell Mutz(Director)John Wesley(Director)

Co-investorsWAWavemaker Three-Sixty Health

Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.

AI & Machine LearningBiotechDeep TechUnited States, US

Co-investorsARARCH Venture PartnersCLClavystBioLELeaps by Bayer

BiotechMenlo Park, US

Ervin Epstein(Executive Officer, Director)inJean Tang(Director)Mark de Souza(Executive Officer)

BoardKatrin Andreasson(Director)

Co-investorsAIAisling Capital

RubiusTX provides independent reviews and research on Australian online casinos, focusing on licensing, player protections, payouts, and responsible gambling standards.

ConsumerGaming

BiotechMedical Devices

Co-investorsARARCH Venture Partners

BiotechDigital HealthMedical DevicesSeattle, US

PAPeter A. Thompson(Executive Officer, Director)in

Co-investorsPOPontifax Venture CapitalRARA CapitalUSUS Venture PartnersNENextech Invest

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

TATimothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)MSMarc Schwabish(Executive Officer)inPMPeter McNamara(Executive Officer)in

Co-investorsVIVida VenturesALAlly Bridge GroupCLClarusPOPolaris PartnersSOSoleus Capital

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)RHReid Huber(Director)inPTPeter Thompson(Director)in

Co-investorsOROrbiMedRARA CapitalNONovo HoldingsOSOsage University PartnersTHThird Rock Ventures

Co-investorsHOHorizons VenturesLULux CapitalTCTCG CrossoverTHThe Column GroupINInnovation Endeavors

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsAGage1ARARCH Venture PartnersCYCycad Group LLCKHKhosla VenturesVEVenrock